Free Research Report Download:
The Cancer Market Outlook To 2014
Free Pharmaceutical Market Research Reports
Corporate & Fiscal
Pharmaceutical Events & Conferences
Terms & Conditions
What are the commercial prospects for anti-smoking treatments? Visiongain's report shows you potential revenues and trends to 2022, discussing data, opportunities and prospects.
Our investigation gives you business research and analysis with sales forecasts. It lets you assess forecasted sales at world market, submarket, product and national level to 2022.
You find analysis of prescription (Rx) and over-the-counter (OTC) therapies for smoking. How will leading products - including Nicorette, Nicotinell and Champix/Chantix - perform from 2012? Our report gives predictions and discussions of sales potential.
Also, you see forecasting of therapeutic categories to 2022, finding potential revenues:
• Over-the-counter (OTC) smoking cessation products
• Prescription (Rx) drugs
• Nicotine replacement therapy (NRT)
• Nicotine receptor partial agonists
• Antidepressant therapy segment.
Our study lets you assess the anti-smoking R&D pipeline too, seeing trends and opportunity. You find discussions of treatments in development:
• Nicotine vaccines
• Monoamine oxidase inhibitors
• Cannabinoid receptor-1 antagonists
• Dopamine D3 antagonists
• Opiate antagonists
• Other agents for smoking therapy.
What does the future hold? From 2012 to 2022, the pharmaceutical industry will improve treatments for smoking cessation, with our report predicting revenue growth. R&D is promising. New formulations and generics will be important too.
Innovations in drug delivery and rising demand in developing countries will also stimulate the industry and market. The study shows you technological and commercial possibilities.
What about leading companies? Our work discusses Pfizer, GSK, Novartis and other players. You see where companies are heading from 2012.
You can investigate the future of medicine for smoking cessation now, finding revenue potentials and other trends.
Sales forecasts, market shares, developmental trends and discussions
In visiongain's report you find revenue forecasting, growth rates and market shares. Also, you see qualitative analyses (SWOT and STEP) and discussion of R&D activities. You receive 34 tables, 29 charts and three research interviews.
Eight ways Smoking Cessation Drugs: World Market Prospects 2012-2022 helps you
In particular, our study gives you the following knowledge on the topic:
• Find potential revenues to 2022 for the world market and submarkets
• Discover projected revenue trends of leading products to 2022
• See market forecasting to 2022 for the US, Japan, EU5, China and India
• Assess leading companies, discovering activities and outlooks
• Review R&D, seeing pipeline trends by therapeutic area
• Investigate competition and opportunities influencing sales
• Find out what will stimulate and restrain the industry and market
• View opinion from our survey, seeing interviews with authorities.
There, you find quantitative and qualitative analyses with independent predictions. You receive information that only our report contains, staying informed on business intelligence.
22nd Century Group
Action on Smoking on Health (ASH)
American Heart Association (AHA)
American Lung Association (ALA)
Australian Therapeutic Goods Administration
Barts and The London School of Medicine and Dentistry
Centers for Disease Control and Prevention (CDC)
Chinese State Tobacco Monopoly Administration (STMA)
European Medicines Agency (EMA)
Food and Drug Administration (FDA)
Independent Pharmaceutica AB
Japanese Ministry of Health, Labour and Welfare (MHLW)
Johnson & Johnson
LSU Health Sciences Center - Shreveport
Medicines and Healthcare Products Regulatory Agency (MHRA)
National Cancer Institute (NCI)
National Health Service (NHS)
National Institute for Health and Clinical Excellence (NICE)
National Institute on Drug Abuse (NIDA)
National Tobacco Corp (China)
Philip Morris Products S.A
Queen Mary University of London
R.J. Reynolds Tobacco Company
Rock Creek Pharmaceuticals
The Cochrane Collaboration
Tobacco Dependence Research Unit
Wolfson Institute of Preventive Medicine
World Health Organization (WHO)